首页 > 市场调查报告书 > 製药

囊肿纤维化治疗药物市场规模、份额和成长分析（按药物类别、给药途径、分销管道和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1898045

囊肿纤维化治疗药物市场规模、份额和成长分析（按药物类别、给药途径、分销管道和地区划分）—产业预测（2026-2033 年）

Cystic Fibrosis Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements), By Route Of Administration (Oral, Inhaled), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计囊肿纤维化治疗市场规模在 2024 年将达到 74.2 亿美元，从 2025 年的 84.7 亿美元成长到 2033 年的 243.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 14.1%。

囊肿纤维化（CF）盛行率的不断上升，以及治疗率的提高，显着推动了对治疗方案的需求。主要市场驱动因素包括私营和政府部门研发投入的增加、非营利主导的增多以及支持性的报销政策。患者数量的增长与对有效CF治疗方法（包括CF药物、支气管扩张剂、祛痰药和各种抗生素）日益增长的需求密切相关。此外，各大製药公司正在研发的药物製剂种类日益丰富，也促进了市场成长。致力于CF的慈善机构，例如CF Worldwide和囊性纤维化组织，透过资助研发，在推动囊肿纤维化治疗进展和拓展市场方面发挥关键作用。

囊肿纤维化治疗市场驱动因素

囊肿纤维化治疗市场成长的关键因素之一是囊性纤维化盛行率的上升。囊肿纤维化是一种影响呼吸系统、消化器官系统和生殖系统的遗传性疾病。此疾病为慢性且无法治愈，患者需终身接受持续治疗。因此，人们对能够有效控制症状并提高患者生活品质的囊肿纤维化治疗方法的需求日益增长。随着医疗服务提供者和患者寻求应对这种复杂疾病相关挑战的解决方案，创新治疗方法的持续需求进一步推动了市场扩张。

囊肿纤维化治疗市场限制因素

囊肿纤维化治疗，尤其是创新标靶治疗的高昂费用，严重阻碍了患者获得治疗。这种经济负担引发了人们对这些药物成本效益的质疑，并可能限制他们获得所需治疗的能力。此外，这些治疗方法的高昂价格也给医疗系统带来压力，并引发了人们对更广泛患者群体治疗永续性和可及性的担忧。因此，成本仍然是囊肿纤维化治疗市场面临的一项重大挑战，对患者和医疗服务提供者都造成了影响。

囊肿纤维化治疗市场趋势

在基因研究进展的推动下，囊肿纤维化治疗市场正呈现出显着的个人化医疗趋势。对导致囊肿纤维化的各种基因突变的深入了解，加速了针对个别患者需求的客製化治疗方法的推出。这种向精准医疗的转变正在推动创新，製药公司致力于开发标靶治疗，以提高治疗效果并改善患者预后。随着新疗法的不断涌现，医疗服务提供者和患者都将积极接受这种个人化医疗模式，从而巩固其在不断发展的囊肿纤维化治疗领域中的重要地位。

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- Vertex Pharmaceuticals（美国）
- 艾伯维（美国）
- 吉利德科学公司（美国）
- 罗氏（瑞士）
- 梯瓦製药工业（以色列）
- 迈兰（现为维亚特里斯）（美国）
- 诺华公司（瑞士）
- 阿斯特捷利康（英国）
- Alaxia
- 艾尔建（现为艾伯维旗下公司）（爱尔兰）
- Beyond Air Inc.（美国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 默克公司（美国）
- Alcresta Therapeutics Inc.（美国）
- 基耶西（义大利）
- 雀巢健康科学（瑞士）
- Pharmaxis有限公司（澳洲）
- PTC Therapeutics, Inc.（美国）
- Insmed公司（美国）
- 格里福尔斯公司（西班牙）

结论与建议

简介目录

Product Code: SQMIG35I2224

Cystic Fibrosis Therapeutics Market size was valued at USD 7.42 Billion in 2024 and is poised to grow from USD 8.47 Billion in 2025 to USD 24.32 Billion by 2033, growing at a CAGR of 14.1% during the forecast period (2026-2033).

The growing prevalence of cystic fibrosis (CF) significantly fuels the demand for therapeutic solutions, alongside increasing treatment rates. Key market drivers include enhanced R&D investment from both private and government sectors, an uptick in nonprofit-driven initiatives, and supportive reimbursement policies. This rising patient population correlates with heightened demand for effective CF therapies, including CFTR modulators, bronchodilators, mucolytics, and various antibiotic formulations. Additionally, the expanding range of drug compositions in development among leading pharmaceutical players contributes to market growth. Charitable organizations dedicated to CF, such as CF Worldwide and the Cystic Fibrosis Organization, play a crucial role by funding research and development efforts, further propelling advancements in cystic fibrosis therapeutics and expanding the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cystic Fibrosis Therapeutics Market Segments Analysis

Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cystic Fibrosis Therapeutics Market

A significant factor propelling the cystic fibrosis therapeutics market is the rising incidence of cystic fibrosis, a genetic disorder that impacts the respiratory, digestive, and reproductive systems. This condition is both chronic and incurable, necessitating continuous treatment throughout a patient's life. As a result, there is a growing demand for effective cystic fibrosis therapies to manage symptoms and improve the quality of life for those affected. The ongoing need for innovative treatment options in this area further fuels market expansion, as healthcare providers and patients seek solutions to navigate the challenges associated with this complex disease.

Restraints in the Cystic Fibrosis Therapeutics Market

The elevated expenses associated with cystic fibrosis treatments, especially the innovative targeted therapies, present a significant obstacle to patient access. This financial burden raises important questions regarding the affordability of these medications for many individuals, potentially limiting their ability to receive necessary care. Furthermore, the high prices of these therapies can strain healthcare systems, creating concerns about sustainability and accessibility for a broader patient population. As a result, the cost factor remains a critical challenge within the cystic fibrosis therapeutics market, affecting both patients and healthcare providers alike.

Market Trends of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is witnessing a notable trend towards personalized medicine, driven by advancements in genetic research. With a deeper understanding of the various mutations that cause cystic fibrosis, there is an increasing push for tailored treatment options that effectively address individual patient needs. This shift towards precision therapy is fostering innovation, as pharmaceutical companies focus on developing targeted therapies that enhance treatment efficacy and patient outcomes. As new treatments emerge, healthcare providers and patients alike are expected to embrace these personalized approaches, solidifying the trend's significance in the evolving landscape of cystic fibrosis care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis

Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Anti-infectives
CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators

Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Oral
Inhaled

Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Cystic Fibrosis Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Class, Route Of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Route Of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Route Of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan (now Viatris) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alaxia.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (now part of AbbVie) (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beyond Air Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcresta Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle HealthScience (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharmaxis Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTC Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insmed, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments